Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-04-24
2007-04-24
Tsang, Cecilia J. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S001690, C530S325000
Reexamination Certificate
active
09937484
ABSTRACT:
The present invention relates to the treatment of pain and to compounds that modulate C-fibre activity. In particular, the present invention relates to the use of a lectin in the manufacture of a medicament for modulation of C-fibre neuron activity, and to lectin conjugates. The lectin conjugates comprise a lectin coupled to a peptide or protein, wherein the peptide or protein is substantially free of Clostridial neurotoxin enzyme activity. The present invention also concerns methods for manufacturing conjugates. The compounds and compositions described have particular application in the treatment of diseases of which C-fibre activity is a component. Such diseases include pain, inflamation, psoriasis and other C-fibre related conditions.
REFERENCES:
patent: 5239062 (1993-08-01), Blattler et al.
patent: 5242687 (1993-09-01), Tykocinski et al.
patent: 5433946 (1995-07-01), Allen, Jr. et al.
patent: 5668255 (1997-09-01), Murphy
patent: 5721207 (1998-02-01), Noble et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6235313 (2001-05-01), Mathiowitz et al.
patent: 2002/0137674 (2002-09-01), Oldham et al.
patent: 197 35 105 (1999-03-01), None
patent: 0 602 686 (1994-06-01), None
patent: WO 92/15327 (1992-09-01), None
patent: WO 93/04191 (1993-03-01), None
patent: WO 93/15766 (1993-08-01), None
patent: WO 94/21300 (1994-09-01), None
patent: WO 94/28923 (1994-12-01), None
patent: WO 95/32738 (1995-12-01), None
patent: WO 96/12802 (1996-05-01), None
patent: WO 96/33273 (1996-10-01), None
patent: WO 97/18790 (1997-05-01), None
patent: WO 98/07864 (1998-02-01), None
patent: WO 98/08540 (1998-03-01), None
patent: WO 99/17806 (1999-04-01), None
patent: WO 91/09871 (1999-07-01), None
Arango, R., et al., “Cloning and sequence analysis of theErythrina cerallodendronlectin cDNA,”FEBS Lett. 264:109-111, Elsevier Science (1990).
Arango, P, et al., “Expression ofErythrina corallodendronlectin inEscherichia coli,” Eur. J. Biochem. 205:575-581, Blackwell Science Ltd. (1992).
Diaz, A. and Dickenson, A.H., “Blockade of spinal N- and P-type, but not L-type, calcium channels inhibits the excitability of rat dorsal horn neurones produced by subcutaneous formalin inflammation,”Pain 69:93-100, Elsevier Science Ireland Ltd. (1997).
Edmonds, B.T. and Koenig, E., “Transmembrane Cytoskeletal Modulation in Preterminal Growing Axons: I. Arrest of Balk and Organello Transport in Goldfish Retinal Ganglion Cell Axons Regenerating In Vitro by Lectins Binding to Sialoglycoconjugates,”Cell Motil. Cytoskeleton 17:106-117, Wiley-Liss, Inc. (1990).
Edmonds, B.T. and Koenig, E., “Transmembrane cytoskeletal modulation in preterminal growing axons. II.Limax flavusagglutinin-induced receptor redistribution, capping and internalization in varicosities of growing axons,”J. Neurocytology 20:232-247, Chapman and Hall Ltd. (1991).
Garber, N., et al., “On the specificity of the : -galactose-binding lectin (PA-I) ofPseudomonas acruginosaand its strong binding to hydrophobic derivatives ot :- galactose and thiocalactose,”Biochem. Biophys. Acta 1116:331-333, Elsevier Science (1992).
Garret, C., et al., “Pharmacological properties of a potent and selective nonpeptide substance P antagonist,”Proc. Natl. Acad. Sci.(USA)68:10208-10212, National Academy of Sciences (1991).
Gupta, D., et al., “Differences in the Cross-Linking Activities of Native and RecombinantErythrina corallodendronLectin with Asialofetuin. Evidence for Carbohydrate-Carbohydrate Interactions in Lectin-Glycoprotein Complexes,”Biochemistry 33:2503-2508, American Chemical Society (1994).
Heilman, R.D., et al., “An Evaluation of the Hot Plate Technique to Study Narcotic Antagonists,”Res. Comm. Chem. Path. Pharm. 13:635-647, PJD Publications Ltd. (1976).
Iglesias, J.L., et al., “Purification and Properties of a O-Galactose/N-Acetyl galactosamine-Specific Lectin fromErythrina cristagalli,” Eur. J. Biochem. 123:247-252, Blackwell Science Ltd. (1982).
Lembeck, F. and Holzer, P., “Substance P as Neurogenic Mediator of Antidromic Vasodilation and Neurogenic Plasma Extravasation,”Naunyn-Schmiedeberg's Arch. Pharmacol. 318:175-183, Springer-Verlag (1979).
Printer, E., et al., “Lack of the evidence for tachykin:n NK2receptor-mediated neutrophil accumulation in the rat cutaneous microvasculature by thermal injury,”Eur. J. Phamacol. 369:91-98, Elsevier Science (Mar. 1999).
Shone, C.C., et al., “A 50-kDo fragment from the NH-terminus of the heavy substrate ofClostridium botulinumtype A neurotoxin forms channels in lipid vesicles,”Eur. J. Biochem. 167:175-180, Blackwell Science Ltd. (1987).
Silverman, J.D. and Kruger, L., “Selective neuronal glycoconjugate expression in sensory and autonomic ganglia: relation of lectin reactivity to peptide and enzyme markers,”J. Neurocytology 19:789-801, Chapman and Hall Ltd. (1990).
Streit, W.J., et al., “Histochemical Localization of Calactose-Containing Glycoconjugate in Sensory Neurons and Their Processes in the Central and Peripheral Nervous System of the Rat,”J. Histochem. Cytochem. 33:1042-1052, The Histochemical Society, Inc. (1985).
Welch, K. and Foster, K., “Chapter 26- Cell Culture of Neurons of the Peripheral Nervous System of Birds and Mammals: 26.1.1 Embryonic Rat Spinal Sensory Ganglia,” inThe Neuron in Tissue Culture,Haynes, L.W., ed., John Wiley & Sons Ltd., New York, N.Y., pp. 389-393 (Dec. 1999).
Zhou, L., et al., “Expression and Purification of the Light Chain of Botulinum Neurotoxin A: A Single Mutation Abolishes Its Cleavage of SNAP 25 and Neurotoxicity after Reconstitution with the Heavy Chain,”Biochemistry 34:15175-15181, American Chemical Society (1995).
English Abstract of European Patent No. EP 0 602 686 A2 from esp@cones database -12.
Bizzini, B., “Investigation of the Mode of Action of Tetanus Toxin With the Aid of Hybrid Molecules Consisting in Part of Tetanus Toxin-Derived Fragments,” inBacterial Protein Toxins,Academic Press London, pp. 427-434 (1984).
Adar, R., et. al., “The amino acid sequence ofErythrina corallodendronlectin and its homology with other legume lectins,”FEBS Lett. 257:81-85, Elsevier Science B.V. (1989).
Arora, N., et. al., “Cytotoxic Effects of a Chimeric Protein Consisting of Tetanus Toxin Light Chain and Anthrax Toxin Lethal Factor in Non-neuronal Cells,”J. Biol. Chem. 269:26165-26171, American Society for Biochemistry and Molecular Biology (1994).
Brinkmann, U., et. al., “A recombinant immunotoxin containing a disulfide-stabilized Fv fragment,”Proc. Natl. Acad. Sci. USA 90:7538-7542, Abstract No. 8356052, National Academy of Sciences (1993).
Kurazono, H., et. al., “Minimal Essential Domains Specifying Toxicity of the Light Chains of Tetanus Toxin and Botulinum Neurotoxin Type A,”J. Biol. Chem. 267:14721-14729, The American Society for Biochemistry and Molecular Biology, Inc. (1992).
Lamb, F. I., et. al., “Nucleotide sequence of cloned cDNA coding for preproricin,”Eur. J. Biochem. 148:265-270, Blackwell Science Ltd. on behalf of the Federation of European Biochemical Societies, (1985).
Law, I. J., “Cloning and expression of cDNA for galactose-binding lectin from peanut nodules,”Plant Science 115:71-79, Elsevier Science Ireland Ltd. (1996).
Lorberboum-Galski, H., et. al., “Cytotoxic activity of an interleukin 2-Pseudomonasexotoxin chimeric protein produced inEscherichia coli,” Proc. Natl. Acad. Sci. USA 85:1922-1926, National Academy of Sciences (1988).
Murphy, J.R., “Diphtheria-related peptide hormone gene fusions: a molecular genetic approach to chimeric toxin development,”Cancer Treat. Res. 37:123-140, Kluwer Academic (1988).
“NeuroBloc (Botulinum Toxin Type B) For Cervical Dystonia Launched in UK,”Doctor's Guide,P/S/L Consulting Group Inc. (Mar. 2001), visited Nov. 28, 2001 at <http://ww.pslgroup.com/dg/1F421
Chaddock John Andrew
Foster Keith Alan
Quinn Conrad Padraig
Audet Maury
Sterne Kessler Goldstein & Fox P.L.L.C.
The Health Protection Agency
Tsang Cecilia J.
LandOfFree
Use of a lectin or conjugates for modulation of c-fibre... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a lectin or conjugates for modulation of c-fibre..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a lectin or conjugates for modulation of c-fibre... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3781921